Safety and side-effects of buprenorphine in the clinical management of heroin addiction

W. Robert Lange, Paul J. Fudala, Elizabeth M. Dax, Rolley E. Johnson

Research output: Contribution to journalArticle

Abstract

Sublingual buprenorphine (8 mg) was administered to heroin-dependent addicts daily for 18 days and continued from day 19 -day 36 either daily or on alternate days. Final data are reported on 18 subjects. The number of self-reported symptoms reviewed as potential adverse drug reactions ranged from 1 to 88 per participant. None was considered to be related definitely to the study medication, and there were no reporting differences between the two dosing regimens. Forty-five reactions were considered probably related to buprenorphine: sedation/drowsiness (three reports) and constipation (42 reports). It was concluded that these were anticipated drug effects rather than adverse reactions. Although some participants showed increases in serum aminotransferase levels, those increases could not be directly attributed to buprenorphine. We conclude that buprenorphine was well tolerated, but further study is needed in this population to delineate the possible attributable risk of the drug to hepatic dysfunction in this population.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalDrug and Alcohol Dependence
Volume26
Issue number1
DOIs
StatePublished - 1990

Fingerprint

Heroin Dependence
Buprenorphine
drug dependence
Heroin
drug
Safety
management
Pharmaceutical Preparations
addiction
Sleep Stages
medication
Constipation
Transaminases
Drug-Related Side Effects and Adverse Reactions
Population
Liver
Serum

Keywords

  • buprenorphine
  • drug therapy
  • heroin addiction

ASJC Scopus subject areas

  • Medicine(all)
  • Behavioral Neuroscience
  • Toxicology
  • Health(social science)

Cite this

Safety and side-effects of buprenorphine in the clinical management of heroin addiction. / Lange, W. Robert; Fudala, Paul J.; Dax, Elizabeth M.; Johnson, Rolley E.

In: Drug and Alcohol Dependence, Vol. 26, No. 1, 1990, p. 19-28.

Research output: Contribution to journalArticle

Lange, W. Robert ; Fudala, Paul J. ; Dax, Elizabeth M. ; Johnson, Rolley E. / Safety and side-effects of buprenorphine in the clinical management of heroin addiction. In: Drug and Alcohol Dependence. 1990 ; Vol. 26, No. 1. pp. 19-28.
@article{8af7bedb01ed49b2b6099ed2e56ec82b,
title = "Safety and side-effects of buprenorphine in the clinical management of heroin addiction",
abstract = "Sublingual buprenorphine (8 mg) was administered to heroin-dependent addicts daily for 18 days and continued from day 19 -day 36 either daily or on alternate days. Final data are reported on 18 subjects. The number of self-reported symptoms reviewed as potential adverse drug reactions ranged from 1 to 88 per participant. None was considered to be related definitely to the study medication, and there were no reporting differences between the two dosing regimens. Forty-five reactions were considered probably related to buprenorphine: sedation/drowsiness (three reports) and constipation (42 reports). It was concluded that these were anticipated drug effects rather than adverse reactions. Although some participants showed increases in serum aminotransferase levels, those increases could not be directly attributed to buprenorphine. We conclude that buprenorphine was well tolerated, but further study is needed in this population to delineate the possible attributable risk of the drug to hepatic dysfunction in this population.",
keywords = "buprenorphine, drug therapy, heroin addiction",
author = "Lange, {W. Robert} and Fudala, {Paul J.} and Dax, {Elizabeth M.} and Johnson, {Rolley E.}",
year = "1990",
doi = "10.1016/0376-8716(90)90078-S",
language = "English (US)",
volume = "26",
pages = "19--28",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Safety and side-effects of buprenorphine in the clinical management of heroin addiction

AU - Lange, W. Robert

AU - Fudala, Paul J.

AU - Dax, Elizabeth M.

AU - Johnson, Rolley E.

PY - 1990

Y1 - 1990

N2 - Sublingual buprenorphine (8 mg) was administered to heroin-dependent addicts daily for 18 days and continued from day 19 -day 36 either daily or on alternate days. Final data are reported on 18 subjects. The number of self-reported symptoms reviewed as potential adverse drug reactions ranged from 1 to 88 per participant. None was considered to be related definitely to the study medication, and there were no reporting differences between the two dosing regimens. Forty-five reactions were considered probably related to buprenorphine: sedation/drowsiness (three reports) and constipation (42 reports). It was concluded that these were anticipated drug effects rather than adverse reactions. Although some participants showed increases in serum aminotransferase levels, those increases could not be directly attributed to buprenorphine. We conclude that buprenorphine was well tolerated, but further study is needed in this population to delineate the possible attributable risk of the drug to hepatic dysfunction in this population.

AB - Sublingual buprenorphine (8 mg) was administered to heroin-dependent addicts daily for 18 days and continued from day 19 -day 36 either daily or on alternate days. Final data are reported on 18 subjects. The number of self-reported symptoms reviewed as potential adverse drug reactions ranged from 1 to 88 per participant. None was considered to be related definitely to the study medication, and there were no reporting differences between the two dosing regimens. Forty-five reactions were considered probably related to buprenorphine: sedation/drowsiness (three reports) and constipation (42 reports). It was concluded that these were anticipated drug effects rather than adverse reactions. Although some participants showed increases in serum aminotransferase levels, those increases could not be directly attributed to buprenorphine. We conclude that buprenorphine was well tolerated, but further study is needed in this population to delineate the possible attributable risk of the drug to hepatic dysfunction in this population.

KW - buprenorphine

KW - drug therapy

KW - heroin addiction

UR - http://www.scopus.com/inward/record.url?scp=0024986342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024986342&partnerID=8YFLogxK

U2 - 10.1016/0376-8716(90)90078-S

DO - 10.1016/0376-8716(90)90078-S

M3 - Article

C2 - 2209411

AN - SCOPUS:0024986342

VL - 26

SP - 19

EP - 28

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1

ER -